Investors should consider buying Glenmark Pharma: Sukhani

Sudarshan Sukhani of s2analytics.com told CNBC-TV18, "Today, Glenmark Pharma could continue with the decline we saw yesterday; that is only for today. F&O expiry creates a lot of confusion which I can’t understand. However, for the larger timeframe I am upbeat on pharma stocks; this is not the end of their bull market and that applies clearly to Glenmark. If it falls more, an investor or a positional trader should consider buying it."At 11:07 hrs Glenmark Pharma was quoting at Rs 948.90, down Rs 44.10, or 4.44 percent. It has touched an intraday high of Rs 990 and an intraday low of Rs 941.40.